Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CannEpil
- Development stage
- Discontinued
- Lead developer
- Argent BioPharma
- Modality
- Small Molecules
- Administration
- Sublingual, Oral
01
Overview
CannEpil is a phytocannabinoid-derived medicinal product developed by Argent BioPharma (formerly MGC Pharmaceuticals) for the treatment of drug-resistant epilepsy. It is formulated as an oral oil-based solution containing a standardized 20:1 ratio of cannabidiol (CBD) to delta-9-tetrahydrocannabinol (THC). The therapeutic effect is primarily attributed to CBD's ability to reduce neuronal hyperexcitability by acting as an antagonist at G protein-coupled receptor 55 (GPR55) and by desensitizing transient receptor potential vanilloid 1 (TRPV1) channels. Additionally, the low concentration of THC acts as a partial agonist at CB1 and CB2 receptors, potentially contributing to the overall anticonvulsant profile through the "entourage effect." CannEpil is currently available in jurisdictions like Australia, the UK, and Ireland through special access schemes or as an unlicensed medicinal product for patients who have not responded to standard anti-epileptic therapies.
- Brand names
- CannEpil
- Other names
- CannEpil 20:1
02
Targets
CYP1B1 (Cytochrome P450 1B1)ENT1 (Solute carrier family 29 member 1)CYP2C9 (Cytochrome P450 family 2 subfamily C member 9)TRPV1 (Transient receptor potential cation channel subfamily V member 1)CYP1A2 (Cytochrome P450 1A2)CNR1 (Cannabinoid receptor 1)CaV3 (Caveolin-3)GPR55 (G protein-coupled receptor 55)FAAHCYP1A1 (Cytochrome P450 1A1)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))
Beyond the preview
Go deeper on CannEpil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CannEpil.